AVALIDE (irbesartan and hydrochlorothiazide) by Sanofi is angiotensin 2 receptor antagonists [moa]. Approved for thiazide diuretic [epc]. First approved in 1997.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AVALIDE is a fixed-dose combination of irbesartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a thiazide diuretic) approved for hypertension treatment. It works by blocking angiotensin II receptors to relax blood vessels and increasing sodium excretion to reduce fluid volume. Patients with hypertension, particularly those requiring dual-agent therapy for adequate blood pressure control, are the primary users.
With LOE approaching and modest Part D spending of $1M on only 1,569 claims in 2023, the brand team is likely small and focused on maximizing remaining patent life through market defense rather than expansion.
Angiotensin 2 Receptor Antagonists
Thiazide Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy
Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
Irbesartan/Hydrochlorothiazide to Control Elevated Blood Pressure to Target in Moderate to Severe Hypertensive Patients
Worked on AVALIDE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on AVALIDE offers limited career growth given its LOE approaching status and minimal linked job count of zero; roles are primarily defensive in nature, focused on protecting market share against generics and optimizing reimbursement. This is a steady-state product suitable for professionals seeking stability rather than rapid advancement, with greater career momentum available on earlier-stage assets.